Risk factors for relapse of antineutrophil cytoplasmic antibody-associated XXXX .

@entity1 @entity1333 @entity2883 @entity1011 @entity7134
OBJECTIVE: To determine the association between characteristics at diagnosis and the time to first relapse in a large cohort of patients with antineutrophil cytoplasmic antibody-associated @entity1333 (AAV). METHODS: We studied long-term followup data from 4 clinical trials that included newly diagnosed @entity1 with a broad spectrum of AAV severity and manifestations. @entity1 and disease characteristics at baseline were used in competing risk regression models with relapse as the event of interest and death as the competing event. RESULTS: We assessed 535 @entity1 with 1,804 @entity1 -years at risk of relapse. At diagnosis, the median age was 60.7 years (interquartile range [IQR] 48.8-69.1 years), 284 @entity1 (53%) had @entity2883 with @entity2883 (Wegener's), and the median @entity1011 level was 203  moles/liter (IQR 97-498). A total of 201 @entity1 (38%) experienced a relapse and 133 @entity1 (25%) died, 96 of whom had not had prior relapse. Anti- @entity7134 antibodies (subhazard ratio [sHR] 1.62 [95% confidence interval 1.39-1.89]) and cardiovascular involvement (sHR 1.59 [95% confidence interval 1.07-2.37]) were independently associated with a higher risk of relapse. Compared with @entity1 with a @entity1011 level  <=100  moles/liter, @entity1 with higher @entity1011 levels had a lower risk of relapse (sHR 0.81 [95% confidence interval 0.77-0.85] for a @entity1011 level of 101-200  moles/liter; sHR 0.39 [95% confidence interval 0.22-0.69] for a @entity1011 level >200  moles/liter). CONCLUSION: Relapse of disease is common for @entity1 with AAV. A @entity1011 level >200  moles/liter at the time of diagnosis is strongly associated with a reduced risk of relapse and may help guide monitoring and treatment of @entity1 with AAV.
